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Abstract
Background: About one third of breast cancer survivors suffer from persistent severe fatigue after completion of
curative cancer treatment. Face-to-face cognitive behavioral therapy (F2F CBT), especially designed for fatigue in
cancer survivors, was found effective in reducing fatigue. However, this intervention is intensive and treatment
capacity is limited. To extend treatment options, a web-based version of CBT requiring less therapist time was
developed. This intervention is aimed at changing fatigue-perpetuating cognitions and behaviors. The efficacy of
web-based CBT will be examined in a multicenter randomized controlled trial.
Methods: In total, 132 severely fatigued breast cancer survivors will be recruited and randomized to either an
intervention condition or care as usual (ratio 1:1). Participants will be assessed at baseline and 6 months thereafter.
The intervention group will receive web-based CBT, consisting of three F2F sessions and maximally eight web-based
modules over a period of 6 months. The care as usual group will be on a waiting list for regular F2F CBT. The total
duration of the waiting list is 6 months. The primary outcome of the study is fatigue severity. Secondary outcomes are
functional impairments, psychological distress and quality of life.
Discussion: If web-based CBT is effective, it will provide an additional treatment option for fatigue in breast cancer
survivors. Web-based CBT is expected to be less time-consuming for therapists than regular F2F CBT, which would
result in an increased treatment capacity. Moreover, the intervention would become more easily accessible for a larger
number of patients, and patients can save travel time and costs.
Trial registration: Dutch Trial Registry - NTR4309
Keywords: Breast cancer, Survivor, Fatigue, Cognitive behavioral therapy, Web-based CBT, E-health, Randomized
controlled trial, Study protocol
Background
Worldwide, breast cancer is the most common malig-
nancy in women. About 1.7 million new cases were diag-
nosed in 2012 [1]. In the last decades, survival rates have
been improved due to early detection by screening pro-
grams and advances in oncological treatments [2, 3].
Since the number of breast cancer survivors increases,
concerns are raised about their long-term well-being.
After completion of curative cancer treatment, side-effects
can become chronic. One of these persistent side-effects is
cancer-related fatigue [3]. The National Comprehensive
Cancer Network defined cancer-related fatigue as “a dis-
tressing, persistent, subjective sense of physical, emotional
and/or cognitive tiredness, related to cancer or cancer
treatment, that is not proportional to recent activity and
interferes with usual functioning” [4]. Once the malig-
nancy is successfully treated, the fatigue is expected to de-
crease. Nevertheless, severe fatigue becomes a chronic
* Correspondence: Harriet.Abrahams@radboudumc.nl
1Expert Center for Chronic Fatigue (ECCF), Radboud University Medical
Center, PO Box 9101, 9166500 HB Nijmegen, The Netherlands
Full list of author information is available at the end of the article
© 2015 Abrahams et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Abrahams et al. BMC Cancer  (2015) 15:765 
DOI 10.1186/s12885-015-1787-7
condition in approximately one-third of breast cancer sur-
vivors [5–8].
Interventions for fatigue in cancer survivors
Since persisting severe fatigue interferes with daily func-
tioning and has profound effects on quality of life, it
should not be left untreated [5, 9]. The evidence of avail-
able interventions was recently evaluated in a practice
guideline of the American Society of Clinical Oncology
[10]. It was concluded that there is evidence for the efficacy
of physical and psychosocial interventions. Initiating or
maintaining adequate levels of physical activity [11–19],
(cognitive) behavioral therapy [20–25], and (psycho)
educational interventions [20, 25, 26] can reduce fatigue.
In addition, there is some evidence for the efficacy of
mindfulness-based approaches [21, 27, 28], yoga [29, 30],
and acupuncture [31, 32].
The current study focuses on one of these evidence-
based interventions: cognitive behavioral therapy (CBT).
A CBT protocol for fatigue in cancer survivors with vari-
ous tumor types was developed and tested in a random-
ized controlled trial (RCT) at our treatment center, the
Expert Center for Chronic Fatigue of the Radboud uni-
versity medical center (Radboudumc) [22]. This RCT
showed that patients reported a clinically significant re-
duction in fatigue and functional impairments following
CBT [22]. These effects were maintained at a 2-year
follow-up [33]. The efficacy of the CBT protocol was re-
cently replicated in a RCT of Prinsen et al. [34]. The
CBT protocol is based on a model of precipitating and
perpetuating factors of fatigue [22]. According to this
model, the malignancy and its treatment are the precipi-
tating factors that induced fatigue. However, other fac-
tors are responsible for the persistence of severe fatigue
after cancer treatment [22]. These fatigue-perpetuating
factors and the overall explanatory model are captured
in Fig. 1. Each fatigue-perpetuating factor is addressed in a
module of the CBT protocol, offered as regular face-to-
face (F2F) therapy. However, this F2F CBT is intensive for
both therapists and patients, since it consists of 12 to 14
F2F sessions over a period of 6 months. Therapists need
to invest considerable time to deliver these sessions and a
limited number of trained cognitive behavioral therapists
provide this F2F therapy. Besides, patients need to travel
to a treatment center to attend the sessions. The develop-
ment of web-based CBT would reduce the therapist time
needed to deliver the intervention and increase treatment
accessibility for severely fatigued breast cancer survivors.
Web-based CBT
The fast-growing field of e-health has created new possi-
bilities in the development of web-based interventions.
Web-based CBT has been developed and examined for a
wide range of mental health problems, and so far, results
are promising. Multiple studies have shown that web-
based CBT can be effective in reducing mental health
problems [35]. To extend treatment options for severely
fatigued breast cancer survivors, we have developed a
web-based version of our F2F CBT protocol for severely
fatigued cancer survivors, named “On the road to recovery”.
The efficacy of this intervention will be examined in a RCT,
named “the CHANGE-study”.
The right time to intervene
In our previous RCT’s examining regular F2F CBT for
severely fatigued cancer survivors, the intervention was
offered at least 1 year after completion of cancer treat-
ment [22, 34]. However, recent research has shown
that the level of fatigue does not decrease further after
3 months following curative cancer treatment [36],
and fatigue-perpetuating factors can already be identi-
fied at 3 months following cancer treatment [37].
Therefore, it might be possible to treat fatigue in can-
cer survivors at an earlier stage. To examine if this is
the case, the web-based CBT will be offered at least
3 months after completion of cancer treatment.
Fig. 1 Explanatory model of the CBT protocol
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Aims of the CHANGE study
1) To examine the efficacy of web-based CBT for
severely fatigued breast cancer survivors on fatigue
severity compared to care as usual.
2) To examine the efficacy of web-based CBT for
severely fatigued breast cancer survivors on
functional impairments, psychological distress,
and quality of life compared to care as usual.
3) To examine if time since completion of cancer
treatment moderates the efficacy of web-based
CBT with respect to fatigue severity.
Methods
The method section of this study protocol is written in
accordance with the CONSORT statement for reporting
parallel group randomized trials [38] and the CONSORT
e-health criteria for reporting web-based interventions [39].
Design
A non-blinded multicenter RCT (the CHANGE-study)
will be conducted to evaluate the efficacy of web-based
CBT compared to care as usual for severely fatigued
breast cancer survivors.
Recruitment
Referrals by medical professionals
Patients will be recruited by medical professionals
(physicians and nurses) at the outpatient clinic of the
departments of surgery and/or oncology of eight hospitals
in the Netherlands (Radboudumc, Nijmegen; Canisius
Wilhelmina hospital, Nijmegen; hospital Gelderse Vallei,
Ede; hospital Bernhoven, Uden; hospital Pantein, Boxmeer;
VieCuri medical center, Venlo; Elkerliek hospital, Hel-
mond; Slingeland hospital, Doetinchem). Physicians and
nurses will inform eligible patients about the study during
regular medical follow-up consults and give them an infor-
mation leaflet. If a patient agrees to be informed about the
study by the researcher, the nurse practitioner will fill out
a participation form and send it to the researcher (HA).
Subsequently, the researcher will call the patient to give
a detailed explanation about the study and to address
questions.
As a second recruitment strategy, nurse practitioners
from selected participating hospitals will identify cohorts of
eligible patients through medical records. They will inform
these cohorts about the CHANGE-study by mail. Patients
will receive an information leaflet with an accompanying
letter. In this letter, patients are asked to contact the re-
searcher if they want to participate in the study.
Self-referrals
Patients will also be informed about the study by leaflets
and notifications on social media of patients’ associations
and the Radboudumc (e.g. Facebook and Twitter). Patients
can complete a participation form, integrated in an in-
formative website. Subsequently, the researcher will
contact patients by phone to inform them about the
study and to address questions.
Participants
All patients who want to participate in the study will
first be screened for eligibility. The in- and exclusion cri-
teria are shown in Table 1. To verify the medical criteria
(criterion 2, 3, and 4) of self-referrals, patients will send
a copy of the most recent report of their medical follow-
up examination to the researcher. The researcher will
administer an online screening questionnaire to verify
the other criteria. All patients will sign informed consent
before filling out this online screening. The Checklist In-
dividual Strength [40] will be used to screen for severe
fatigue (criterion 6). The Beck Depression Inventory for
Primary Care (BDI-PC) [41, 42] will be used to screen
for a depressive disorder (criterion 9). If the score on the
BDI-PC is ≥4, the researcher will administer the Depres-
sion module of the Mini-International Neuropsychiatric
Interview (M.I.N.I.) [43] by phone to assess the presence
of a major depression. If patients meet the criteria for
major depression, they will be advised to contact their
general practitioner for an appropriate referral.
Procedure
If patients are eligible and have signed written informed
consent, they will start with a baseline assessment (T0).
Following T0, participants will be randomized to either the
intervention condition (web-based CBT) or the control
Table 1 In- and exclusion criteria
Inclusion criteria
1) Women who are 18 years or older.
2) Treated for breast cancer with curative intent.
3) Breast cancer treatment (surgery, chemo- and/or radiotherapy) must
be finished at least 3 months previously. There is no upper limit for
the time since completion of cancer treatment. Patients who
currently receive hormone and/or targeted therapy are eligible.
4) Disease-free at entry of the study, defined by the absence of
somatic disease activity parameters.
5) Able to speak, read, and write Dutch.
6) Severely fatigued, defined by a score of ≥35 on the fatigue severity
subscale of the Checklist Individual Strength.
7) Having access to a computer with internet.
Exclusion criteria
8) Presence of a co-morbidity that explains the presence of severe
fatigue.
9) A depressive disorder, assessed with the BDI-PC and the M.I.N.I.
10) Current psychological treatment for a psychiatric disorder.
11) Current CBT for fatigue.
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condition (care as usual). After 6 months, all participants
will be assessed again (T1). For participants assigned to the
web-based CBT, this will be the post-intervention assess-
ment. The overall study design is shown in Fig. 2. A test
assistant will perform T0, T1 and the randomization.
Randomization
Stratified randomization will be based on time since
completion of cancer treatment (3 months up to 1 year
versus ≥ 1 year) and type of referral (referrals by medical
professionals versus self-referrals). After T0, randomization
will be performed by a test assistant in the presence of the
patient. A computerized randomization tool, built by an in-
dependent statistical expert, will be used to randomly allo-
cate patients to either intervention or control condition.
The allocation ratio will be 1:1 and block-randomization
will be used with a block size of six. The test assistant, the
researcher and the participants will be blinded to the alloca-
tion sequence. Theywill not be blinded for the randomization
outcome, because this is not possible in psychological
treatments.
Intervention
Development
On the road to recovery is built in a web portal, designed
with technical guidance from the Psychological and Psy-
chiatric Care Innovation (Utrecht, The Netherlands) [44].
Experts in the field of fatigue in cancer survivors devel-
oped the content of this web portal. Trained, experienced
cognitive behavioral therapists (HK, TB) and researchers
(MGI, HA) wrote the texts and assignments. In total, the
web portal consists of 13 texts and 26 assignments. A
graphic designer developed the lay-out of On the road to
recovery, and a videographer made 13 videos together with
a therapist (HK) and the researcher (HA). These videos
are integrated in the web portal. In the first video, a med-
ical oncologist (SV) explains the rationale of the CBT. The
other 12 videos are interviews of three cancer survivors.
These patients are recovered from fatigue after receiving
F2F CBT, and tell about their experiences with the CBT
modules. A screenshot of the web portal is provided in
Fig. 3. For this occasion, the text is translated into English.
Usability testing
Five severely fatigued breast cancer survivors, who were
following F2F CBT, participated in a test pilot. The us-
ability of the web portal was tested by using a “think
aloud procedure” [45]. Participants were asked to think
aloud while independently completing the modules. In
the meanwhile, the researcher (HA) noted obstacles they
encountered (i.e. usability problems and problems with
text readability). Afterwards, all participants filled out a
feedback form. They were asked about the sufficiency of
information provided, text readability, and the lay-out
and usability of the web portal. The findings of the us-
ability testing were used to optimize the final version of
the web portal.
Intervention condition: on the road to recovery
All participants in the intervention condition will follow
On the road to recovery, a web-based version of the
regular F2F CBT for severely fatigued cancer survivors.
Participants will start with two F2F sessions with their
therapist. In these sessions, the CBT model for fatigue in
cancer survivors (Fig. 1) will be explained and a treat-
ment plan will be made. Thereafter, participants will fol-
low On the road to recovery online. The web-based CBT
consists of eight treatment modules. All participants will
start with setting their treatment goals (module 1). Then,
they will work on the fatigue-perpetuating factors that
are applicable to them: (1) poor coping with breast can-
cer and breast cancer treatment; (2) high fear of cancer
recurrence; (3) dysfunctional fatigue-related cognitions;
(4) a deregulated sleep-wake rhythm; (5) a deregulated
activity pattern; and/or (6) negative social interactions and
low social support. Each of these six fatigue-perpetuating
factors coincides with a treatment module (module 2–7).
At baseline assessment, it is decided which modules are
relevant for each participant. Finally, all participants will
complete the therapy by realizing their treatment goals
(module 8). On the road to recovery is tailor-made.
Fig. 2 Overall study design. T0 = baseline assessment;
T1 = second assessment
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Assessment tools are used to assess which fatigue-per-
petuating factors are present and to determine which treat-
ment modules patients need to follow (Table 2). All
treatment modules consist of three parts: psycho-education
(“READING”), assignments in which participants work on
fatigue-perpetuating factors (“DOING”) and a final as-
signment, in which participants evaluate their progress
(“REVIEW”). The content of the eight treatment modules
is described in more detail in Additional file 1.
Therapists will contact patients two-weekly by e-mail to
give feedback on their progress and to answer questions.
Therapists can also initiate video sessions with a secured
video consultation system (Facetalk) [46]. These video ses-
sions are in particular recommended for the modules
“Fear of cancer recurrence” and “Coping with cancer and
cancer treatment”. The guideline is to plan maximally two
video sessions. The maximum duration of On the road
to recovery is 6 months. Therapists will be blinded for
the level of fatigue severity (primary outcome measure).
Only after the post-treatment assessment (T1), they
will be informed about the levels of fatigue severity on
T0 and T1. The outcomes with respect to fatigue severity
and other disabilities will be discussed with the participant
in a final F2F session. In this session, the therapist and
patient will determine if the patient is recovered from
severe fatigue. If patients are not recovered from se-
vere fatigue, F2F therapy will be offered outside the
study context.
Treatment integrity
On the road to recovery will be given by licensed cogni-
tive behavioral therapists. All therapists are experienced
in working with the F2F CBT protocol for severe fatigue
in cancer survivors. They will participate in a weekly
supervision, in which cases are discussed in the presence
of senior clinical psychologists (HK, TB). Changes in in-
dividual treatment plans will be made according to the
study protocol and to the CBT principles for severely fa-
tigued cancer survivors.
At the end of the study, a random 5 % of the e-mail
messages send to the patients will be evaluated. An ex-
perienced clinician (HK) and researcher (HA) will deter-
mine whether the web-based CBT was delivered according
to the predefined treatment protocol. To determine if web-
based CBT is less time consuming than F2F CBT, therapists
will register the invested time for each patient.
Control condition: care as usual
Participants in the control condition will be on a waiting
list for regular F2F CBT for fatigue in cancer survivors.
The total duration of the waiting list is 6 months. In this
period, patients will receive care as usual. The usual care
for breast cancer survivors in the Netherlands consists
of follow-up examinations conform the Dutch guidelines
for oncology care [47]. The frequency of these follow-up
examinations depends on age, time since diagnosis and a
possible BRCA1/2 mutation. In general, there will be a
3-month follow-up in the first year, a biannual follow-up
in the second year, and an annual follow-up in the fol-
lowing years up to 5 years after diagnosis.
Recently, a guideline for the management of psy-
chosocial distress in breast cancer survivors is imple-
mented [48]. According to this guideline, psychosocial
problems are identified and patients should be referred to
Fig. 3 Screenshot of On the road to recovery
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Table 2 Tools to assess which treatment modules are indicated
Treatment module Instrument [REF] Outcome Response format Psychometric properties Cut-off value
1. Coping with
cancer and cancer
treatment
Impact of Event Scale [62] Intrusion and avoidance 4-point Likert scale, range 0–60 Cronbach’s α ranges between 0.87
and 0.96; adequate convergent
validity [63]
Score ≥10 for each
separate scale
2. Fear of cancer
recurrence
Modified cancer acceptance
scale [53]
Fear of disease recurrence 4-point Likert scale, range 3–12 N/A Score ≥7
Cancer worry scale [64] Worries about the risk of
developing cancer (again)
4-point Likert scale, range 8–32 Cronbach’s α = 0.87; good convergent
and divergent validity [64]
Score ≥14 [64]
3. Helpful thinking Modified causal attribution
list [52, 65]
Somatic and non-somatic
attributions
4-point Likert scale Cronbach’s α ranges between 0.71
and 0.77 [65]
N/A
Illness management
questionnaire [65–67]
Focusing on symptoms 6-point Likert-scale, range 9–54 Cronbach’s α ranges between 0.85
and 0.93 [66]
Score ≥30
Fatigue catastrophizing
scale [68]
Catastrophizing in
response to fatigue
5-point Likert scale, range 1–5 Cronbach’s α = 0.85 [68] Score ≥2
(magnifying); score
≥7 (ruminating).
Self-efficacy scale [33, 65] Self-efficacy with respect
to fatigue
4 point Likert scale, range 7–28 N/A Score ≤19
4. Sleep-wake rhythm Sleep-wake diary Sleep-wake rhythm Bedtimes and wake-up times of 12
consecutive days and nights
N/A N/A
5. Activity regulation An actometer, a motion-sensing device,
worn to the ankle for 12 consecutive days
and nights
Activity pattern (relatively
active versus low active)
Average physical activity level
(number of accelerations per 5 min
period) [69]
Adequate reliability and validity [73] N/A
6. Social support Van Sonderen Social Support Inventory,
subscales Interactions (SSLI) and
Discrepancies (SSLD) [70]
Discrepancy between
actual and desired social
support
4-point Likert Scale, range 34–136 Cronbach’s α = 0.93 (SSLI); α = 0.95
(SSLD); good content validity [71]
Score ≥14 (SSLI);
score ≥50 (SSLD)
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specialized care providers. Participants may therefore be
referred to other fatigue-oriented interventions during the
study (e.g. psychosocial interventions, a rehabilitation tra-
jectory, or physical therapy). At T1, all participants will be
asked if they have received any treatment for fatigue dur-
ing the study, and if so, they are asked to describe this
treatment.
Outcomes
Primary outcome
Fatigue severity, measured by the subscale Fatigue Severity
(8 items, 7-point Likert Scale) of the Checklist Individual
Strength (CIS) [49]. This subscale consists of eight items,
scored on a 7-point Likert scale. The range of scores is 8 to
56, with a higher score indicating a higher level of fatigue.
The cut-off score for severe fatigue is ≥35 [49]. The CIS has
been established as a valid and reliable measure [50, 51],
which showed sensitivity to detect change in previous stud-
ies investigating fatigue in cancer survivors [22, 33, 52, 53].
Secondary outcomes
Functional impairments, measured by the Sickness Impact
Profile 8 (SIP) [54, 55]. This questionnaire addresses the
level of disability in eight domains: alertness behavior, sleep/
rest, homemaking, leisure activities, mobility, social interac-
tions, ambulation, and work. The weighted total score on
these eight domains will be used to assess functional
disability, with higher scores indicating more disabil-
ities. The SIP is a reliable measure with sufficient content
validity [56].
Psychological distress, measured by the total score on
the Brief Symptom Inventory 18 (BSI-18) [57]. This
multidimensional questionnaire consists of 18 items,
scored on a 5-point Likert scale. The range of scores is
0 to 72, with a higher score indicating more psychological
distress. The BSI-18 is a shortened version of the Symp-
tom Checklist 90 (SCL-90) [58]. The BSI-18 has high
levels of sensitivity and specificity [59].
Quality of life, measured by the European Organization
for Research and Treatment of Cancer Quality of Life
Questionnaire Core 30 (EORTC-QLQ-C30) [60]. This
questionnaire consists of 30 items that cover five function
scales (physical, role, cognitive, emotional and social func-
tioning), three symptom scales (fatigue, pain, and nausea
and vomiting), and a global health and quality of life
scale. All scales are scored on a 4-point Likert scale.
The EORTC-QLQ-C30 has been established as a valid
and reliable measure [61].
Other variables
Demographic variables will be assessed by using a self-
report questionnaire at T0. The instruments used to de-
termine the relevant fatigue-perpetuating factors are
shown in Table 2.
Power
The sample size calculation is based on the guidelines of
Borm et al. for analysis of covariance (ANCOVA) in RCT’s
[72]. A clinically relevant difference of six points is ex-
pected for the primary outcome (fatigue severity subscale
of the CIS) between the intervention and control condi-
tion. This difference is based on a study of Knoop et al.
[73], in which the efficacy of a minimal intervention for
patients with chronic fatigue syndrome was examined
[73]. A minimum number of 60 patients per condition
would be needed for a t-test with an alpha of 0.05, a two-
sided significance level and a power of 0.85. According to
Borm et al. [72], this number of patients needs to be
multiplied by a “design factor” to calculate the needed
sample size for an ANCOVA [76]. This factor is one
minus the squared correlation coefficient between the
baseline and outcome measure of fatigue severity. In our
previous study examining the efficacy of F2F CBT for fa-
tigue in cancer survivors, the correlation of the baseline
and outcome measure was 0.36 [22, 33]. This leads to a
factor of 0.87 (1 - .362 = 0.87). Thus, the minimal number
of patients in each condition is 53 (60*0.87 = 52.2) . The
drop-out rate in our first RCT examining F2F CBT for fa-
tigue in cancer survivors was 13 % [22, 33]. In the current
study, patients might experience less support from their
therapist in the web-based CBT. Therefore, the drop-out
in the current RCT is estimated to be 50 % higher than in
the first RCT (1,5*13 = 19,5 %) Therefore, a margin of
19,5 % for drop-out is added to the minimal number of 53
patients per condition. This results in a sample size of 132
severely fatigued breast cancer survivors.
Intended statistical analyses
The primary objective of the study is to examine the ef-
fects of web-based CBT on reducing fatigue severity
compared to care as usual. Therefore, an analysis of co-
variance (ANCOVA) will be used with the CIS-fatigue
score at T1 as dependent variable, the CIS-fatigue score
at T0 as covariate and condition as fixed factor [39]. The
clinical importance of the treatment effect will be deter-
mined. Differences between the intervention and control
condition on the amount of change in fatigue severity
will be calculated on T0 and T1. Clinically meaningful
change will be defined as a reliable change index of
more than 1.96 and a decrease of the fatigue level to a
normal range (i.e. a score of <35 on the fatigue severity
subscale of the Checklist Individual Strength). The ef-
fects of web-based CBT on the secondary outcomes of
the study (functional impairments, psychological distress
and quality of life) compared to care as usual will be de-
termined with ANCOVA’s. For each secondary outcome
measure, an ANCOVA will be performed with the score
of the outcome measure at T1 as dependent variable,
the score at T0 as covariate and condition as fixed
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factor. The third objective of the study is to examine if
time since completion of cancer treatment moderates
the effects of web-based CBT. This will be analyzed with
an ANCOVA with time since completion of cancer
treatment (3 months-1 year versus ≥1 year) as covariate.
The CIS-fatigue score at T1 will be the dependent vari-
able, and the fatigue score at T0 will be the second co-
variate. All data analyses will be based on intention to
treat. Missing values on primary and secondary outcome
measures will be replaced with multiple imputation
using fully conditional specification with at least five im-
putations. In case of statistically significant differences, a
sensitivity analysis will be performed, based on different
assumptions about the values of missing data.
Ethical approval
This study has been reviewed and approved by the Med-
ical Ethical Committee of the Radboudumc (reference no.
2013/167). The study has also been approved by the local
ethical committees of each participating hospital (Radbou-
dumc, Canisius Wilhelmina hospital, hospital Gelderse
Vallei, hospital Bernhoven, hospital Pantein, VieCuri med-
ical center, Elkerliek hospital and Slingeland hospital). The
study is registered in the Dutch Trial Registry (reference
no. NTR4309, date registered: December 6, 2013).
Discussion
The CHANGE study will examine the efficacy of a web-
based version of an evidence-based CBT protocol for se-
vere fatigue in breast cancer survivors. The efficacy of the
intervention on fatigue, functional impairments, psycho-
logical distress and quality of life will be examined as well.
Web-based CBT has several advantages over F2F CBT; (i)
e-mail contacts are expected to be less time consuming
for therapists than F2F contacts, which would result in an
increased treatment capacity; (ii) the intervention becomes
more easily accessible for a larger number of patients, and
(iii) the burden for patients can be reduced, because they
can save travel time and costs to the treatment center. Be-
sides, patients can work on the intervention at their own
pace, at any preferred time.
After completion of the patient inclusion, the CHANGE
study will be extended to form a non-inferiority trial. In this
trial, stepped care will be compared to F2F CBT for severely
fatigued breast cancer survivors. The first step in the
stepped care condition will be web-based CBT. If patients
are not recovered from severe fatigue after completion of
web-based CBT, additional F2F CBT sessions will be of-
fered. We will examine whether the effects of stepped care
on fatigue severity are noninferior to regular F2F CBT after
a waiting period. We will also determine whether stepped
care requires less therapist time than regular F2F CBT. The
non-inferiority trial is registered in the Dutch Trial Registry
(reference no. NTR5179).
In conclusion, if web-based CBT is effective, it would
provide an additional treatment option that is easily ac-
cessible for breast cancer survivors suffering from severe
fatigue.
Additional file
Additional file 1: Overview of the treatment modules of On the
road to recovery. (DOCX 64.3 kb)
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